Journal
ELIFE
Volume 11, Issue -, Pages -Publisher
eLIFE SCIENCES PUBL LTD
DOI: 10.7554/eLife.80813
Keywords
P; falciparum; hemoglobin digestion; aminopeptidase; drug target; P; falciparum
Categories
Funding
- National Health and Medical Research Council [1185354, 1136300]
- Australian Government
Ask authors/readers for more resources
The study demonstrates the importance of leucine aminopeptidase PfA-M17 for the survival of Plasmodium falciparum, providing parasites with essential amino acids for growth. Loss of PfA-M17 results in parasites exhibiting multiple digestive vacuoles at the trophozoite stage.
authors Abstract Plasmodium falciparum, the causative agent of malaria, remains a global health threat as parasites continue to develop resistance to antimalarial drugs used throughout the world. Accordingly, drugs with novel modes of action are desperately required to combat malaria. P. falciparum parasites infect human red blood cells where they digest the host's main protein constituent, hemoglobin. Leucine aminopeptidase PfA- M17 is one of several aminopeptidases that have been implicated in the last step of this digestive pathway. Here, we use both reverse genetics and a compound specifically designed to inhibit the activity of PfA- M17 to show that PfA- M17 is essential for P. falciparum survival as it provides parasites with free amino acids for growth, many of which are highly likely to originate from hemoglobin. We further show that loss of PfA- M17 results in parasites exhibiting multiple digestive vacuoles at the trophozoite stage. In contrast to other hemoglobin degrading proteases that have overlapping redundant functions, we validate PfA- M17 as a potential novel drug target.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available